Breast cancer stem cells (BCSC) are resistant to conventional chemotherapy and radiation, which may destroy tumor masses but not all BCSC that can mediate relapses. In the present study, we showed that the level of Wnt/β-catenin signaling in BCSC is relatively higher than in bulk tumor cells, contributing to a relatively higher level of therapeutic resistance. We designed a highly potent small molecule inhibitor, CWP232228, which antagonizes binding of β-catenin to TCF in the nucleus.
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inhibit the Wnt/β-catenin pathway under in vitro culture systems, the poor pharmacokinetic and pharmacodynamic (PK/PD) profiles of these molecules have prevented in vivo preclinical investigations. Therefore, the development of inhibitors that target β-catenin and exhibit better in vivo PK/PD profiles is needed. Herein, we designed a highly potent, selective small molecule inhibitor, namely CWP232228 (U.S. Patent 8,101,751 B2), which antagonizes the binding of β-catenin to the TCF protein in the nucleus and specifically down-regulates a subset of Wnt/β-catenin-responsive genes. In vitro and in vivo studies revealed that CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of BCSCs and bulk tumor cells. The dysregulation of insulin-like growth factor-I (IGF-I) signaling in primary breast cancers has been associated with radio-resistance and tumor recurrence (20) . Although IGF-I is important for the development of breast cancer, the role of this protein in BCSCs remains unclear. We also demonstrated, for the first time, the attenuation of IGF-I-mediated BCSC sphere formation mediated by CWP232228. Taken together, these results suggest that targeting β-catenin-mediated transcription using CWP232228 has significant therapeutic potential for the treatment of breast cancer. 6 concentrations of CWP232228. After 48 h of incubation, cell viability was assessed by cell counting kit-8 (CCK-8, Rockville, Maryland) according to the manufacturer's instruction. The numbers of viable cells were measured at a wavelength of 450 nm using Versamax microplate reader.
Real-time PCR , stem cell PCR array, and Wnt signaling pathway PCR array
Total RNA was extracted using TRIzol reagent (Invitrogen). RNA purity was verified by measuring 260/280 absorbance ratio. The first strand of cDNA was synthesized with 2 mg of total RNA using SuperScript II (Invitrogen), and one-tenth of the cDNA was used for each PCR mixture containing Express SYBR-Green qPCR Supermix (BioPrince, Seoul, Korea). Real-time PCR was performed using a Rotor-Gene Q (Qiagen, Hilden, Germany). The reaction was subjected to 40-cycle amplification at 95°C for 20 sec, at 60°C for 20 sec and at 72°C for 25 sec. Relative mRNA expression of selected genes was normalized to HPRT and quantified using the DDCT method. The Technologies, Vancouver, Canada) was used to isolate the population with a high ALDH enzymatic activity. Cells were stained for ALDH using the Aldefluor reagent according to the manufacturer's 7 instructions and analyzed on FACS Calibur. As negative control, for each sample of cell aliquot was treated with 50 μM DEAB, a specific ALDH inhibitor. Aldefluor pos cells were quantified by calculating the percentage of total fluorescent cells compared with a control staining reaction. FACS Aria was used to sort Aldefluor-stained cells into Aldefluor neg and Aldefluor pos cell population.
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The use of fresh breast tumor specimens was approved by the research ethic committees at the Korea National Cancer Center. Informed consent was obtained from all patients. Samples were fixed with 4% paraformaldehyde for fluorescent staining. Samples were permeabilized with 0.3 M glycine and 0.3%
Triton X-100, and nonspecific binding was blocked with 2% normal swine serum (DAKO, Glostrup, Denmark). Staining was performed as described previously (23) , using the primary anti-ALDH1
(Abcam, Cambridge, UK) and anti-LEF1 (Cell Signaling Technology). Alexa Fluor 488-conjugated rabbit IgG (Molecular Probes, Eugene, OR) was used to visualize ALDH1 and LEF1. Samples were examined by fluorescence microscopy (Zeiss LSM 510 Meta). The calculation of ALDH1 and LEF1 expression was based on green fluorescence area and density divided by cell number, as determined from the number of DAPI-stained nuclei, in three randomly selected fields for each specimen from a total of three independent experiments. For quantitation, an arbitrary threshold was set to distinguish specific from background staining, and this same threshold setting was applied to all the samples analyzed.
Short hairpin RNA
Small hairpin RNA (shRNA) targeting mouse IGF-I and non-targeting RNA were purchased from Sigma (St. Louis, MO, USA). For the efficient IGF-I shRNA transfection, reverse transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. We chose the IGF-I shRNA that is most effective in mRNA levels from five shRNA designed from the target sequence and determined by qRT-PCR and ELISA. 
Animal study

Lung metastasis animal model
For the metastasis and survival experiment, 9-week-old female BALB/c mice were inoculated with 5x10 4 4T1-Luc cells into the tail vein in 0.1 mL volume. After inoculation, the mice were randomly assigned to treatment groups (i.p at CWP232228 100mg/kg in PBS) and control group. Mice were euthanized and lungs were collected on 3 weeks, and fixed with 10 % buffered formalin. Metastasis incidence was assessed via in vivo bioluminescence measurement using an IVIS spectrum (Caliper Life Sciences). For luciferase detection, 150 mg/mL D-luciferin(Caliper Life Sciences) in PBS was injected intraperitoneally before imaging. Photometric measurement of metastasis was done by Living
Image software (V. 3.1.0, Caliper Life Sciences).
In vivo limiting dilution assay
For the limiting dilution experiment, primary tumors were minced using scissors and incubated in DMEM (Invitrogen) mixed with collagenase/hyaluronidase(Stem cell Technologies) at 37°C for [15] [16] [17] [18] [19] [20] min. Primary tumor-derived cells were inoculated into the m.f.p. of mice at varying cell densities ranging from 500 to 50000 cells in a total volume of 50 µL volume (n = 8 for each group). 4T1 and MDA-MB-435 cells-injected mice were euthanized on three and seven weeks, respectively and secondary tumors were excised for analysis. The frequency of tumor-initiating cells (TICs) was calculated using ELDA webtool (http://bioinf.wehi.edu.au/software/elda). The volume of the primary tumor was measured as previously described [33] .
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Statistical analysis
All the statistical data were analyzed by GraphPad Prism 5. 1A ).
Previous studies have demonstrated that aldehyde dehydrogenase 1 (ALDH1) is a marker of both normal and malignant human mammary stem cells and a predictor of poor clinical outcomes (30), and lymphoid enhancer-binding factor-1 (LEF1), is a critical regulator of Wnt/β-catenin signaling (31). The β-catenin inhibitor CWP232228 suppresses BCSC growth and clonogenicity Using a cell-based reporter system, we screened a diverse library of low molecular weight compounds for the inhibition of Wnt/β-catenin-mediated transcriptional activity. The results showed that CWP232228 was the most effective Wnt/β-catenin inhibitor (Supplementary fig. 9A ). A pharmacokinetic/pharmacodynamic (PK/PD) analysis in mice indicated that CWP232228, administered i.v. at a dose of 200 mg/kg, generated an exposure of the compound in the blood at a concentration greater than 0.8μg/ml for 7h (Supplementary fig. 9B ; Supplementary. table 3). Next, we further tested the efficacy and specificity of CWP232228 to inhibit Wnt/β-catenin signaling in breast cancer cells transiently transfected with a luciferase reporter plasmid in the presence or absence of Wnt3a. In response to CWP232228 treatment, the transcriptional activity in breast cancer cells was significantly decreased in a dose-dependent manner ( Fig. 2A) . Using western blot analysis ( As a functional assay, we evaluated the effect of CWP232228 on primary and secondary sphere formation. Treatment with CWP232228 resulted in the disruption of primary sphere formation of both 4T1 and MDA-MB-435 cells in a dose-dependent manner (Fig. 2D ). For the secondary sphereforming assay, treated primary spheres were collected and dissociated into single cells. The cells from treated or untreated primary spheres were re-plated on culture dishes without additional treatment.
Interestingly, we observed that in the presence of CWP232228, the cells derived from primary spheres did not form secondary spheres as efficiently as the cells from untreated spheres (Fig. 2D) . Moreover, we evaluated the effect of CWP232228 on the sphere formation of primary breast cancer cells fig. 4A-D) . These findings suggest that CWP232228 was sufficient to block subsequent secondary sphere formation from primary spheres in the absence of additional treatment.
In breast carcinomas, cell populations with high levels of ALDH activity are enriched in tumorigenic stem/progenitor cells (32). Therefore, we hypothesized that CWP232228 might disrupt BCSC sphere formation by regulating ALDH activity. To test this hypothesis, we used FACS analysis to investigate the effect of CWP232228 on ALDH activity. Indeed, the treatment of 4T1 and MDA-MB-435 cells with CWP232228 for 48h decreased the size of the ALDH-positive subpopulation (Fig. 2E) . In this context, we examined the expression of BCSC markers in the presence or absence of CWP232228.
Consistent with our hypothesis, the expression levels of these markers, including the phenotypes Sca- 
CWP232228 targets chemoresistant BCSCs
It is important to compare CWP232228 with another well-known small molecule inhibitor (FH535) that targets the β-catenin/Tcf protein-protein interactions. Because deregulated cell proliferation is a hallmark of cancer cells, the anti-proliferative effects of these two compounds were determined using the MTT assay. Overall, these data showed that CWP232228 more effectively suppressed the proliferative potential of MDA-MB-435 cells and at much lower doses than the well-known small molecule inhibitor FH535 (Supplementary fig. 5A ). Normal human fibroblast cell-based dosedependent experiments showed no marked signs of toxicity at the CWP232228 dose used in this study (Supplementary fig. 5B ).
Recently, it has been suggested that BCSCs are resistant to many conventional therapeutic approaches, tumors. To investigate the association between chemoresistance and Wnt/β-catenin signaling, we evaluated the available breast cancer datasets using the Oncomine dataset repository (www.oncomine.org). After specifically filtering for breast cancer datasets showing a response or nonresponse to conventional docetaxel treatment, we observed significant correlations between chemoresistance and the expression of negative (GSK3β) or positive (TCF4) regulators of Wnt/β-catenin signaling (Fig. 3A and B) . Importantly, we observed that both the size of ALDH-positive populations and the sphere formation in 4T1 and MDA-MB-435 cells increased in response to conventional docetaxel treatment. However, the docetaxel-enriched ALDH-positive populations ( 
CWP232228 reduces tumor growth in a murine xenograft model
We further investigated the in vivo efficacy of CWP232228 on tumorigenesis using a mouse xenograft model. Importantly, CWP232228 treatment (100 mg/kg, administered intraperitoneally) resulted in a significant reduction in tumor volume (Fig. 4A-C) . No significant changes in mortality (Supplementary fig. 6A ), body weight (Supplementary fig. 6B ), hematologic values (Supplementary fig. 6C ), and hemolytic potential (Supplementary fig. 6D ) were observed, indicating that CWP232228-associated toxicity was minimal. No obvious clinical signs, including anorexia, salivation, diarrhea, vomiting, polyuria, anuria, and fecal changes, were observed. Additionally, no significant differences in body weight were observed in mice inoculated with cancer cells (Supplementary fig. 11 ). To determine whether and to what extent CWP232228 treatment affects the proportion of BCSCs in vivo, we performed FACS analysis to quantitate the percentage of the total cell population with ALDH activity in primary bulk tumors with or without CWP232228 treatment.
Indeed, CWP232228 treatment led to a smaller ALDH-positive subpopulation ( Fig. 4D and E) . The anti-tumor effects of CWP232228 were further confirmed using serially regenerated secondary tumor 16 xenografts derived from primary tumor tissues without additional treatment (Fig. 4F and G) . (Table 1) . Therefore, CWP232228 did not decrease the repopulation frequency of functional BCSCs in a xenograft model.
CWP232228 targets BCSCs, bulk tumors, and metastatic tumors
An ideal and completely curative breast cancer treatment targets both BCSCs and bulk tumor cells to prevent recurrence. For each xenotransplant, we observed the significant inhibition of tumor growth induced through CWP232228 treatment alone or in combination with docetaxel (Fig. 5A) . Docetaxel treatment alone moderately impacted tumor growth (Fig. 5A) . In bulk tumors, the percentage of ALDH1-positive cells increased with conventional docetaxel treatment (Fig. 5B) . However, these docetaxel-enriched ALDH-positive populations were markedly reduced after CWP232228 treatment (Fig. 5B) . Moreover, we used metastatic i.v. 4T1 cell models to investigate the effects of CWP232228 on the metastasis of breast cancer. We used cells stably expressing firefly luciferase and whole-body bioluminescence to non-invasively detect intravenously injected xenografts. Lung metastasis was significantly lower in the CWP232228-treated groups than in the untreated control groups (Fig. 5C ).
An overall increase in the survival of animals treated with CWP232228 was also observed (Fig. 5D ).
These results indicated that CWP232228 treatment alone is effective against conventional docetaxelenriched BCSC populations, bulk tumors, and metastatic tumors in vivo. 
Suppressive effects of CWP232228 on BCSCs are achieved through the disruption of IGF-I activity
We compared the expression of downstream components of Wnt/β-catenin signaling between sphereforming cells and monolayer cells and between non-treated and drug-treated spheres to identify potential downstream targets of CWP232228 using a Wnt/β-catenin target PCR array. We screened differentially expressed genes associated with Wnt/β-catenin signaling. Two criteria for the selection of gene expression differences were employed: a significant t-test and fold-change magnitude. Among the genes examined, the level of IGF-I mRNA was significantly enhanced (≥9-fold up-regulated) in BCSCs (Fig. 6A) . Interestingly, in both Wnt/β-catenin targeting PCR array (Fig. 6B ) and immunocytochemical analysis (Fig. 6C) , CWP232228 treatment was correlated with decreased IGF-I levels (≥8-fold down-regulated) under sphere-forming conditions. Previous studies demonstrated that the expression of IGF-I in breast cancer tissues (35) and serum levels of this protein in breast cancer patients (36) are significantly higher than those in healthy individuals. Therefore, it is reasonable to hypothesize that CWP232228 suppresses the growth of BCSCs and bulk tumors through the disruption of IGF-I activity. Consistently, these results revealed that compared with control cells, IGF-I knockdown (Supplementary fig. 12 ) led to smaller ALDH-positive subpopulations (Fig. 6D ) and decreased BCSC sphere formation (Fig. 6E) . The stimulatory effects of IGF-I on BCSC sphere formation were successfully attenuated after CWP232228 treatment (Fig. 6F) . To further evaluate the CWP232228-mediated inhibition of IGF-I secretion, we performed an ELISA to quantitate the levels of IGF-I in both monolayer and sphere cultures with or without CWP232228 treatment. Consistent with immunocytochemical results, CWP232228 treatment significantly decreased IGF-I secretion under sphere-forming conditions (Supplementary fig. 13 ). These results suggest that the suppressive effects of CWP232228 on BCSCs are achieved through the disruption of IGF-I activity. Here, to inhibit the growth and/or self-renewal capacity of BCSCs through the suppression of β-catenin-mediated signaling, we used the small molecule inhibitor CWP232228, identified in a highthroughput screen. Follow up analyses using this compound revealed a reduction in the expression of a Wnt/β-catenin luciferase reporter and the inhibition of the expression of the Wnt/β-catenin target gene LEF1 ( Fig. 2A-C) . Notably, whereas the inhibition of β-catenin-mediated transcription through CWP232228 had inhibitory effects on the growth of BCSCs and bulk tumor cells, BCSCs showed a markedly greater degree of growth inhibition (Fig. 3-5) . Moreover, CWP232228 treatment was sufficient to block subsequent secondary BCSC sphere formation in vitro (Fig. 2D ) and secondary tumor development in the xenograft model (Table. 1), without additional treatment. These findings suggest that CWP232228 inhibits the initiation of tumor development and disrupts the physiological requirements for BCSC maintenance. The observation of markedly reduced ALDH-positive BCSC populations in bulk tumors treated with CWP232228 further supports this interpretation ( Fig. 4D and   E ).
Breast cancer is likely to metastasize to multiple organs, primarily including the lungs, liver, and the brain. Therefore, we investigated the effect of CWP232228 on metastasis using breast cancer cell xenograft models. For this purpose, the mice were intravenously injected with mouse breast cancer cells expressing firefly luciferase (4T1-Luc), and the cells were non-invasively detected based on bioluminescence. CWP232228 significantly reduced tumor bioluminescence in a fast-growing metastatic model of mouse breast cancer. This decrease in 4T1-Luc cells reflects both the number of metastatic cancer cells (data not shown) and the tumor volume as the bioluminescent signal was measured across the whole body, integrating both optical parameters (Fig. 5C) . Importantly, this efficacy was achieved without affecting primary toxicity parameters, such as mortality, body weight, hematologic values, and hemolytic potential (Supplementary fig. 6 ). 
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The aberrant activation or transcriptional activity of β-catenin has been correlated with breast stem cell amplification and tumorigenesis in a number of studies (16) . Moreover, studies aiming to target CSCs have primarily focused on disrupting their self-renewal capacity rather than directly causing toxic effects; these drugs could therefore be less toxic than conventional cytotoxic chemotherapeutic drugs, as reflected by their higher than anticipated IC 50 values (44). This result suggests that the β-catenin/TCF interaction, rather than other Wnt/β-catenin signaling components could be an effective therapeutic target in BCSCs. (20) . These studies might eventually reveal a role for IGF-I in breast malignancies with respect to tumor growth, metastatic progression, and resistance to therapy.
Although the IGF-I system is important in breast cancer development, the mechanisms underlying the potential role of this protein in BCSCs remain largely unknown. Crosstalk between IGF-I and Wnt/β-catenin signaling was recently reported in colon cancer (47), oligodendroglial cells (48), and chondrocytes (49). Therefore, the interactions between these two signaling pathways in BCSCs are intriguing and need further investigation. In the present study, we also provided the first evidence that IGF-I is expressed at higher levels in BCSCs than in non-BCSCs. Furthermore, we observed an attenuating effect of CWP232228 on IGF-I-mediated functions in BCSC sphere formation and ALDH-positive BCSC populations (Fig. 6) . The importance of IGF-I in the growth and/or selfrenewal capacity of BCSCs is consistent with previous observations from breast cancer cell lines (50).
These studies suggest that IGF-I signaling is critical for the tumorigenicity and maintenance of BCSCs, and these cells could be selectively targeted to improve clinical outcomes through the inhibition of BCSCs.
In summary, these results provide the first demonstration that the small molecule inhibitor CWP232228 inhibits Wnt/β-catenin signaling and depletes BCSCs from bulk tumors. BCSC-depleted tumor cell populations showed diminished self-renewal capacity and decreased tumorigenicity. These findings suggest that the inhibition of Wnt/β-catenin signaling suppresses the growth and functionality of BCSCs, which might be key drivers of breast cancer metastasis and recurrence. To the best of our knowledge, the effect of CWP232228 on breast tumorigenesis has not previously been assessed.
Taken together, these results suggest that by antagonizing the binding of β-catenin to the TCF protein in the nucleus, β-catenin inhibitors, specifically CWP232228, might be novel BCSC-targeting agents for the treatment of breast cancer. MB-435 cells) following inoculation. The BCSC frequency was calculated using the extreme limiting dilution assay (ELDA) (F-G) . The results are presented as the means ± SD from three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. 
